Hosted on MSN23m
Privia Health (NASDAQ:PRVA) Surprises With Q4 Sales But Full-Year Sales Guidance Misses ExpectationsHealthcare tech company Privia Health Group (NASDAQ:PRVA) announced in Q4 CY2024, with sales up 4.6% year on year to $460.9 ...
Key Takeaways Supermicro shares jumped 12% on Wednesday after the server maker submitted its delayed financial reports just ...
U.S. stock index futures rose on Thursday as AI bellwether Nvidia's upbeat forecast soothed concerns of cooling demand in the ...
Hosted on MSN23m
Sotera Health Company’s (NASDAQ:SHC) Q4 Earnings Results: Revenue In Line With ExpectationsHealthcare services company Sotera Health (NASDAQ:) in Q4 CY2024, but sales fell by 6.5% year on year to $290.2 million. Its ...
45mon MSN
Supermicro filed annual financial reports late after an accounting dispute with ex-auditor EY.EY dropped Supermicro as a ...
Hosted on MSN23m
Nexstar Media (NASDAQ:NXST) Beats Q4 Sales TargetsLocal broadcasting and digital media company Nexstar (NASDAQ:NXST) reported Q4 CY2024 results , with sales up 14.1% year on ...
4h
Stocktwits on MSNB. Riley Retail Traders Eye Short Covering As Next Key Catalyst After Nasdaq Compliance WinB. Riley stock (RILY) stock gained 3.2% in aftermarket trade on Wednesday after jumping more than 35% in the regular trading ...
StockStory.org on MSN15h
Beyond Meat (NASDAQ:BYND) Exceeds Q4 ExpectationsPlant-based protein company Beyond Meat (NASDAQ:BYND) announced in Q4 CY2024, with sales up 4% year on year to $76.66 million ...
Hosted on MSN14h
SunOpta (NASDAQ:STKL) Posts Q4 Sales In Line With EstimatesPlant-based food and beverage company SunOpta (NASDAQ:STKL) in Q4 CY2024, with sales up 6.8% year on year to $193.9 million.
Super Micro also filed results for the first two quarters of the fiscal 2025 year and said it has "regained compliance" with ...
Hosted on MSN14h
Kratos (NASDAQ:KTOS) Misses Q4 Sales Targets, Stock DropsAerospace and defense company Kratos (NASDAQ:KTOS) in Q4 CY2024 as sales rose 3.4% year on year to $283.1 million. Next ...
Hosted on MSN14h
Sarepta Therapeutics’s (NASDAQ:SRPT) Q4: Beats On RevenueBiotech company Sarepta Therapeutics (NASDAQ:SRPT) announced in Q4 CY2024, with sales up 65.9% year on year to $658.4 million ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results